U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7NO2.ClH
Molecular Weight 173.597
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINOBENZOIC ACID HYDROCHLORIDE

SMILES

Cl.NC1=CC=C(C=C1)C(O)=O

InChI

InChIKey=KBCPMQUSOLSAQO-UHFFFAOYSA-N
InChI=1S/C7H7NO2.ClH/c8-6-3-1-5(2-4-6)7(9)10;/h1-4H,8H2,(H,9,10);1H

HIDE SMILES / InChI

Molecular Formula C7H7NO2
Molecular Weight 137.136
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14850772 | https://www.ncbi.nlm.nih.gov/pubmed/14774206 | https://www.ncbi.nlm.nih.gov/pubmed/14779043 | https://www.ncbi.nlm.nih.gov/pubmed/18150079 | https://www.ncbi.nlm.nih.gov/pubmed/21402476

AMINOBENZOATE SODIUM is a salt of Aminobenzoic acid. Aminobenzoic acid is an intermediate in the synthesis of folate by bacteria, plants, and fungi. Many bacteria, including those found in the human intestinal tract such as E. coli, generate Aminobenzoic acid from chorismate by the combined action of the enzymes 4-amino-4-deoxychorismate synthase and 4-amino-4-deoxychorismate lyase. Plants produce Aminobenzoic acid in their chloroplasts, and store it as a glucose ester (pABA-Glc) in their tissues. Humans lack the enzymes to convert Aminobenzoic acid to folate, so require folate from dietary sources such as green leafy vegetables. In humans, Aminobenzoic acid is considered nonessential and, although it has been referred to historically as "vitamin Bx", is no longer recognized as a vitamin, because most people have colon bacteria that generate Aminobenzoic acid. The potassium salt is used as a drug against fibrotic skin disorders, such as Peyronie's disease, under the trade name Potaba.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8400.0 nM [Ki]
8130.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Pabalate

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
9 g multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Disc. AE: DRESS syndrome...
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Other AEs: Skin infection, Oral candidiasis...
Other AEs:
Skin infection (8.3%)
Oral candidiasis (25%)
Pneumonia (8.3%)
Cushing's syndrome (8.3%)
Steroid acne (8.3%)
Diabetes mellitus (16.7%)
Anaemia (8.3%)
Neurosis (8.3%)
Sources:
2 g 3 times / day multiple, oral
Studied dose
Dose: 2 g, 3 times / day
Route: oral
Route: multiple
Dose: 2 g, 3 times / day
Co-administed with::
tamsulosin
finasteride
Sources:
unhealthy, 70 years
n = 1
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: 70 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hepatitis acute...
AEs leading to
discontinuation/dose reduction:
Hepatitis acute
Sources:
3 g 4 times / day multiple, oral
Recommended
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
unhealthy, mean age 49 years
n = 51
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: mean age 49 years
Sex: M
Population Size: 51
Sources:
Disc. AE: Gastrointestinal disorders, Pruritus...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders (7.8%)
Pruritus (2%)
Fever (2%)
Chills (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
DRESS syndrome Disc. AE
9 g multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Diabetes mellitus 16.7%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Oral candidiasis 25%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Anaemia 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Cushing's syndrome 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Neurosis 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Pneumonia 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Skin infection 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Steroid acne 8.3%
150 mg 1 times / day multiple, intramuscular (mean)
Studied dose
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
prednisolone(36.1 mg; daily)
Sources:
unhealthy, 56.6 years
n = 12
Health Status: unhealthy
Condition: pemphigus vulgaris
Age Group: 56.6 years
Sex: M+F
Population Size: 12
Sources:
Hepatitis acute Disc. AE
2 g 3 times / day multiple, oral
Studied dose
Dose: 2 g, 3 times / day
Route: oral
Route: multiple
Dose: 2 g, 3 times / day
Co-administed with::
tamsulosin
finasteride
Sources:
unhealthy, 70 years
n = 1
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: 70 years
Sex: M
Population Size: 1
Sources:
Chills 2%
Disc. AE
3 g 4 times / day multiple, oral
Recommended
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
unhealthy, mean age 49 years
n = 51
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: mean age 49 years
Sex: M
Population Size: 51
Sources:
Fever 2%
Disc. AE
3 g 4 times / day multiple, oral
Recommended
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
unhealthy, mean age 49 years
n = 51
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: mean age 49 years
Sex: M
Population Size: 51
Sources:
Pruritus 2%
Disc. AE
3 g 4 times / day multiple, oral
Recommended
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
unhealthy, mean age 49 years
n = 51
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: mean age 49 years
Sex: M
Population Size: 51
Sources:
Gastrointestinal disorders 7.8%
Disc. AE
3 g 4 times / day multiple, oral
Recommended
Dose: 3 g, 4 times / day
Route: oral
Route: multiple
Dose: 3 g, 4 times / day
Sources:
unhealthy, mean age 49 years
n = 51
Health Status: unhealthy
Condition: Peyronie’s disease
Age Group: mean age 49 years
Sex: M
Population Size: 51
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
SODIUM para-aminobenzoate and accepted brands omitted from new and nonofficial remedies.
1950 Nov 11
Sodium para-aminobenzoate therapy of eczema-dermatitis.
1951 Jul
Patents

Patents

Sample Use Guides

Sodium para-aminobenzoate has been administered orally in doses of 2 grams every two hours
Route of Administration: Oral
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO2 hydration activity. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10–20 mM Hepes (pH 7.5, for the a-CAs) or TRIS (pH 8.3, for the b-CAs) as buffers, and 20 mM Na2SO4 or 20 mM NaClO4 (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of AMINOBENZOATE SODIUM (1 mM) were prepared in distilled–deionized water and dilutions up to 0.1 nM were done thereafter with distilled–deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E–I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes from Lineweaver–Burk plots, as reported earlier, and represent the mean from at least three different determinations.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:52 GMT 2023
Edited
by admin
on Fri Dec 15 15:06:52 GMT 2023
Record UNII
FP470XT8FS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINOBENZOIC ACID HYDROCHLORIDE
Common Name English
BENZOIC ACID, 4-AMINO-, HYDROCHLORIDE (1:1)
Systematic Name English
4-AMINOBENZOIC ACID HYDROCHLORIDE
Systematic Name English
BENZOIC ACID, P-AMINO-, HYDROCHLORIDE
Systematic Name English
P-AMINOBENZOIC ACID HYDROCHLORIDE
Systematic Name English
BENZOIC ACID, 4-AMINO-, HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
22669-27-8
Created by admin on Fri Dec 15 15:06:52 GMT 2023 , Edited by admin on Fri Dec 15 15:06:52 GMT 2023
PRIMARY
PUBCHEM
12209225
Created by admin on Fri Dec 15 15:06:52 GMT 2023 , Edited by admin on Fri Dec 15 15:06:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID50945336
Created by admin on Fri Dec 15 15:06:52 GMT 2023 , Edited by admin on Fri Dec 15 15:06:52 GMT 2023
PRIMARY
FDA UNII
FP470XT8FS
Created by admin on Fri Dec 15 15:06:52 GMT 2023 , Edited by admin on Fri Dec 15 15:06:52 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE